<DOC>
	<DOCNO>NCT00121719</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) lenvatinib patient solid tumor lymphomas .</brief_summary>
	<brief_title>An Open Label Phase I Dose Escalation Study Of E7080</brief_title>
	<detailed_description>This open-label , non-randomized , dose escalation study . Patients treat lenvatinib daily . Each four-week treatment period consider one treatment cycle . The selection subsequent dose level perform accord accelerated design : Although initially 3 patient per dose level enter , next dose level open patient accrual first patient previous cohort completes Cycle 1 drug-related toxicity great grade 1 ( except alopecia , lymphopenia anemia ) .</detailed_description>
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must meet inclusion criterion outline order eligible participate study : 1 . Patients histologically and/or cytologically confirm solid tumor lymphoma resistant/refractory approve therapy appropriate therapy available . 2 . All previous treatment ( include surgery radiotherapy ) must complete least four week prior study entry acute toxicity must resolve . 3 . Aged great equal 18 year . 4 . Karnofsky performance status great equal 70 % . 5 . Written inform consent participate study . EXCLUSION CRITERIA : Patients follow characteristic eligible study : 1 . Brain tumor brain leptomeningeal metastasis . 2 . Any following laboratory parameter : 1. hemoglobin less 9 g/dl ( 5.6 mmol/L ) 2. neutrophil less 1.5 x 10^9/L 3. platelet less 100 x 10^9/L 4. serum bilirubin great 25 micromol/l ( 1.5 mg/dl ) 5. liver parameter great 3 x upper limit normal ( ULN ) 6. serum creatinine great 1.5 x ULN creatinine clearance le 60 ml/minute 3 . Uncontrolled infection . 4 . Clinically significant cardiac impairment unstable ischemic heart disease include myocardial infarction within six month study start . 5 . Any treatment investigational drug within 30 day start study . 6 . Pregnancy lactation ( woman childbearing potential must negative pregnancy test inclusion study ; postmenopausal woman must amenorrheic least 12 month ) . Female patient childbearing potential must use adequate contraceptive protection , define two form contraception , one must barrier method . 7 . Fertile male willing use contraception whose female partner use adequate contraceptive protection . 8 . History alcoholism , drug addiction , psychiatric psychological condition , opinion investigator , would impair study compliance . 9 . Legal incapacity . 10 . Centrally locate squamous cell carcinoma lung . 11 . Proteinuria great 1+ bedside test . 12 . History gastrointestinal malabsorption . 13 . Surgery involve gastro and/or intestinal anastomosis within four week study start . 14 . Patients bleed thrombotic disorder . 15 . Patients use therapeutic dosage anticoagulant . 16 . Poorly control hypertension ( defined change hypertensive therapy within three month study start ) patient diagnose hypertension ( define repeat blood pressure measurement 160/90 mmHg high ) screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Resistant refractory solid tumor</keyword>
	<keyword>lymphoma</keyword>
	<keyword>hodgkin disease</keyword>
	<keyword>non-hodgkins lymphoma</keyword>
	<keyword>neoplasm</keyword>
</DOC>